Jeffrey W. Albers
CIK 1638474 · CEO AND PRESIDENT · last filed 2026-08-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BPMC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
300 TECHNOLOGY SQ, 8TH FLOOR
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SYRE | Director | 24,360 | $92.91 | $2.26M | -$2.66M | 7 | 2026-08-10 |
| KYMR | Director | 0 | $114.84 | $0 | -$1.80M | 13 | 2026-06-25 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 0 | $129.46 | $0 | -$62.43M | 69 | 2025-07-21 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 1 | 2023-11-27 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Director | 260 | $11.19 | $2.9K | $0 | 5 | 2022-06-30 |
Recent Filings · Page 4 of 12
115 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-10-25 | SYRE | Notice (144) | −7,000 | -$235.9K | EDGAR |
| 2024-09-11 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | −9,702 | -$1.33M | EDGAR |
| 2024-09-09 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −19,702 | -$1.69M | EDGAR |
| 2024-08-26 | KYMR | Notice (144) | −5,000 | -$238.9K | EDGAR |
| 2024-08-26 | KYMR | Mixed | — | -$193.8K | EDGAR |
| 2024-06-20 | KYMR | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +2,242 | $0 | EDGAR |
| 2024-05-16 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2024-03-26 | Blueprint Medicines Corp (BPMC) Delisted | Sell (S) | −11,033 | -$1.00M | EDGAR |
| 2024-03-22 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | — | -$2.01M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.